[[To comply with academic institution
guidelines, the founders' academic affiliations and roles are
listed only at the end of the statement.]]
BOSTON, May 1, 2024
/PRNewswire/ -- Somite Therapeutics, a tech-bio company
leveraging big data and AI to introduce novel cell replacement
therapies, today announced that the Company will present a poster
at the upcoming American Society of Cell and Gene Therapy (ASGCT)
Meeting, taking place May 7 – 11,
2024, in Baltimore, MD and
virtually.
Somite Therapeutics to present at the 27th
Annual Meeting of the American Society of Cell and Gene Therapy
(ASGCT)
Kristy J. Brown, Ph.D., SVP of
Translational Development at Somite Therapeutics, will be
presenting Somite's platform that leverages AI to optimize
cell differentiation protocols for large-scale production of
differentiated muscular, dermal, tendon and skeletal (bones and
cartilage) human cells harnessing somite-derived cells derived from
human pluripotent stem cells (PSCs). See full abstract here.
Additionally, a poster from the laboratory of Olivier Pourquie,
Ph.D., a scientific co-founder of Somite Therapeutics, will
highlight the latest developments of muscle differentiation
protocol that allowed Somite to double the proportion of
satellite cells in human iPS-derived myogenic cultures and enhanced
the maturity/fusion ability as demonstrated in an in vivo
model. See full abstract here.
Founded in October 2023, Somite is building AI foundation
models to produce human tissue at scale for cell therapies. These
therapies have the potential to treat a wide range of diseases that
involve the loss or deficiency of cell populations, such as
diabetes, obesity, and muscular dystrophies.
The founding team comprises six distinguished experts in their
respective fields: Dr. Micha Breakstone, a seasoned AI entrepreneur
who successfully sold Chorus.ai, serves as the CEO. Joining him are
the CTO, Dr. Jonathan Rosenfeld, who pioneered AI scaling
laws at MIT, along with Boston-based scientists Dr.
Olivier Pourquie, Dr. Allon Klein, Dr. Cliff Tabin, and
Dr. Jay Shendure, who bring
expertise in developmental biology, stem cells, single cell
analysis, and computational biology.
About Somite
Somite.ai is a venture-backed company
aiming to become the OpenAI of stem cell biology,
developing AI foundation models to produce human tissue for cell
therapies at scale for diseases such as diabetes, obesity, and
muscular dystrophies. Somite's AI platform, AlphaStem,
fuels a virtuous cycle: It enables new cell therapies, generating
massive data that further improve the platform, empowering even
faster therapy creation with broader applications.
Incorporated in Oct. 2023, Somite.ai
has raised $5.3m to date.
Somite Management Team:
- Micha Breakstone, PhD: CEO and Co-founder - Repeat AI
entrepreneur (Chorus.ai acq. for $575m)
- Jonathan Rosenfeld, PhD: CTO
and Co-founder - Head of the Fundamental AI group at MIT
FutureTech
- Carl Morris, PhD: Chief
Scientific Officer
- Kristy Brown, PhD: SVP
Translational Development
Scientific Co-founders:
- Olivier Pourquie, PhD: Professor of Genetics and Pathology,
Harvard Medical School and Brigham and
Women's Hospital
- Allon Klein, PhD: Associate
Professor of Systems Biology at Harvard
Medical School
- Cliff Tabin, PhD: Chair of
the Department of Genetics at Harvard Medical
School
- Jay Shendure, PhD: HHMI
Professor of Genome Sciences at University of
Washington
Media Contact: media-relations@somite.ai
Website: www.somite.ai
View original content to download
multimedia:https://www.prnewswire.com/news-releases/somite-therapeutics-to-present-at-the-27th-annual-meeting-of-the-american-society-of-cell-and-gene-therapy-asgct-302132921.html
SOURCE Somite Therapeutics